2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.07C.09 Neoadjuvant Chemoimmunotherapy (CIT) In Resectable Non-Small Cell Lung Cancer (NSCLC): Real-World Treatment Patterns and Surgical Outcomes

EP.07C.09 Neoadjuvant Chemoimmunotherapy (CIT) In Resectable Non-Small Cell Lung Cancer (NSCLC): Real-World Treatment Patterns and Surgical Outcomes

Back to course

Pdf Summary

The study examines the real-world application of neoadjuvant chemoimmunotherapy (CIT) in patients with resectable non-small cell lung cancer (NSCLC) at Stages I-III in Alberta, Canada. Funded by the Glans-Look Lung Cancer Database, the research focuses on understanding treatment patterns, responses, surgical outcomes, and adverse events associated with CIT, which combines platinum-based chemotherapy with nivolumab, an immune checkpoint inhibitor (ICI).<br /><br />The study identifies 55 patients who received CIT, noting that this approach is increasingly part of the standard care due to its potential to enhance both event-free and overall survival by leveraging a robust immune response. The treatment aims to shrink tumors before surgery and help prevent micrometastatic disease through immune surveillance post-resection.<br /><br />Key findings include:<br />- 40 surgical resections were performed, with 15% of patients deemed ineligible for surgery due to progressive disease or other factors like residual N2 disease.<br />- 29% experienced CIT-related adverse events requiring changes or discontinuation in treatment. Notably, immune-related adverse events included colitis, rash, and pneumonitis.<br />- Post-operative complications were noted in 37% of cases, primarily due to air leaks, though severe complications like sepsis and respiratory failure also occurred, resulting in a median hospital stay of six days.<br />- At the time of analysis, three recurrences were observed within one year of resection, indicating a recurrence rate that remains significant despite surgical interventions.<br /><br />The study concludes that neoadjuvant CIT provides substantial benefits, particularly for Stage III disease in terms of nodal downstaging and pathological responses. However, there is a need to manage adverse effects and recognize complex surgical outcomes. The findings align with clinical trial results, suggesting that real-world application of CIT yields meaningful pathological responses.

Asset Subtitle

Amanda Gibson

Meta Tag

Speaker Amanda Gibson

Topic Early-Stage Non-small Cell Lung Cancer

Keywords

neoadjuvant chemoimmunotherapy

non-small cell lung cancer

NSCLC

platinum-based chemotherapy

nivolumab

immune checkpoint inhibitor

surgical outcomes

adverse events

pathological responses

Alberta Canada